INTRODUCTION {#s1}
============

Non-invasive circulating tumor DNA (ctDNA) genotyping is a cost-effective alternative to tumor biopsies when these biopsies are associated with significant risk, tumor tissue is insufficient or inaccessible, and/or serial assessment of tumor molecular abnormalities is needed to optimize treatment. ctDNA analysis of epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) and v-Ki-ras2 kirsten rat sarcoma viral oncogene homolog (KRAS) in colorectal cancer (CRC) is well established \[[@R1], [@R2]\]. However, validation studies of the clinical relevance of ctDNA in other tumor types \[[@R3]\] are lacking.

In this systematic review, we summarize the published trials of ctDNA analysis by tumor type and across tumor types, and we discuss the role of ctDNA analysis in selecting patients for enrollment in clinical trials and in guiding targeted therapy. The potential use of plasma genotyping in cancer is illustrated in [Figure 1](#F1){ref-type="fig"}.

![Potential use of plasma genotyping in cancer.\
Early stage disease: *Screening* will require the use of large *NGS* panels, with both high sensitivity and perfect specificity. *Before surgery*, determination of tumor burden in plasma has the potential to help guide neo-adjuvant or adjuvant therapy and monitor response, using large panels or patient-specific assays based on the molecular profile of the tissue biopsy when available. *After surgery*, NGS (large gene panels or patient-specific assays) can detect MRD and guide adjuvant therapy (early detection) or detect relapse. Low tumor shed in plasma will be the main limitation to the integration of plasma genotyping in early stage disease. Advanced stage disease: *At diagnosis*, ctDNA can guide genotype-directed therapy (using targeted assays focusing on a predefined gene of interest (i. e. *EGFR* in NSCLC) or targeted NGS covering genes of interest). The variations in allelic fractions allow for monitoring of treatment response, which may be helpful for pharmacodynamics analyses in phase I studies. *When acquired resistance* to targeted therapies occurs, ctDNA can detect specific mechanisms of resistance (targeted assay like for *EGFR* T790M or targeted NGS), taking into consideration the different clones present within the primary tumor (P) and all metastatic sites (M1, M2), and guide treatment adjustments.](oncotarget-11-188-g001){#F1}

Non-small cell lung cancer {#s1_1}
--------------------------

The increasing number of "targetable" genotypes in NSCLC and understanding of tumor resistance to targeted therapies has led to rapid, non-invasive, longitudinal assays to repeatedly assess tumor biology throughout treatment.

ctDNA for NSCLC genotyping in advanced-stage NSCLC {#s1_2}
--------------------------------------------------

The combination of more targetable genotypes and minimally invasive diagnostic tools (e. g. endobronchial ultrasound) that result in small specimens \[[@R4]--[@R6]\] has led to the development of alternative, noninvasive testing methods, such as the U. S. Food and Drug Administration (FDA)-approved targeted ctDNA assay (Cobas) for *EGFR* genotyping or the CLIA (Clinical Laboratory Improvement Amendments)-certified plasma droplet digital polymerase chain reaction (ddPCR) assay. ddPCR is a highly sensitive (*EGFR* exon 19 deletion, 82%; *EGFR* L858R mutation, 74%) and quantitative approach that allows for the longitudinal monitoring of treatment response \[[@R7], [@R8]\]. Although the specificity of these PCR-based platforms allows for the initiation of EGFR-targeted therapy on the basis of positive plasma testing, negative results must be confirmed by tumor tissue genotyping \[[@R9]\]. While most clinically validated assays are focused on a single predefined gene, next-generation sequencing (NGS) of ctDNA can broadly interrogate the tumor molecular profile across a range of genes and variant types. Hybrid capture-based NGS platforms have already been evaluated in NSCLC \[[@R10]--[@R12]\]. Overall, 75% of patients with NSCLC harbor potentially actionable genomic aberrations in ctDNA, although concordance with tissue is suboptimal (specificity, 63.5%) \[[@R11], [@R13]--[@R15]\].

Tumor NGS can help monitor tumor dynamics and detect acquired *ALK* resistance mutations in crizotinib-resistant patients \[[@R14]\]. Our group has studied various NGS methods and found favorable diagnostic accuracy using a bias-corrected targeted ctDNA NGS (2/3 *ALK*; 2/3 *RET*; 2/2 *ROS1*) \[[@R16]\] or using amplicon-based sequencing (6/7 *ALK*; 2/2 *ROS1*) \[[@R17]\]. A larger prospective study is needed to determine the most reliable method for identifying targetable fusions in ctDNA.

At disease progression, ctDNA constitutes a promising alternative to tissue biopsies and is a well-established approach in the *EGFR* setting. Plasma genotyping is widely used as a screening test for detection of the EGFR T790M resistance mutation, with tumor biopsy needed only if the result is negative \[[@R1], [@R17], [@R18]\]. It remains unknown, however, if treatment should be adjusted on the basis of isolated plasma variations. Ongoing trials, such as the (APPLE)-EORTC study \[[@R19]\], will help determine the value of ctDNA analysis in treatment selection.

Clinical trials that validated the use of plasma NGS to guide therapy have demonstrated encouraging results \[[@R20]--[@R22]\]. In 323 patients with NSCLC, the addition of ctDNA analysis to tissue NGS analysis increased the identification of driver alterations and resulted in an 85.7% rate of objective response or stable disease \[[@R20]\].

Screening and minimal residual disease in early-stage NSCLC {#s1_3}
-----------------------------------------------------------

The National Lung Screening Trial \[[@R23]\] and the Dutch-Belgian Randomized Lung Cancer Screening Trial (NELSON) \[[@R24]\] demonstrated that low-dose computed tomography (CT) screening reduces the mortality rate in lung cancer. Benign lung nodules (false positives) generate invasive procedures. Deep ctDNA sequencing is a more specific and potentially complementary approach to low-dose CT screening in lung cancer but is limited by the low or absent DNA shed of early-stage tumors \[[@R25], [@R26]\]. Combining ctDNA with other circulating biomarkers such as transcriptomics (ctRNA) could improve sensitivity, while white blood cell sequencing to eliminate "false-positive" variants linked to clonal hematopoiesis may increase specificity \[[@R27]--[@R29]\].

ctDNA analysis is also used to detect minimal residual disease (MRD) with plasma genotyping. Tumor molecular profiles from previous biopsies are used to build personalized PCR-based assays with improved sensitivity and specificity. In the TRACERx study, ctDNA from 100 patients was analyzed at the time of diagnosis and followed after definitive treatment. Patient-specific multiplex PCR assays (threshold: ≥2 variants for positivity) demonstrated high sensitivity (93%) and specificity for MRD detection \[[@R26], [@R30]\].

In another study, ctDNA was analyzed using cancer personalized profiling by deep sequencing (CAPP-seq) in 255 samples from 40 patients with stage I--III lung cancer (stage II--III, *n* = 33) treated with curative intent and 54 healthy adults. It found that in 94% of patients with stage I--III lung cancer with disease recurrence, ctDNA was detectable in the first post-treatment blood sample and preceded radiographic progression by 5.2 months (median), indicating that detection of post-treatment ctDNA should prompt treatment tailored to the patient's ctDNA analysis to prevent disease progression \[[@R31]\].

Gastrointestinal tract cancers {#s1_4}
------------------------------

### Esophageal carcinoma {#s1_4_1}

ctDNA analysis of patients with squamous cell carcinoma (SCC) of the esophagus with the use of a 90-gene panel was associated with sensitivity of 94% and 75%, respectively, when detecting ≥1 or ≥2 mutant genes, suggesting that ctDNA analysis can help monitor treatment effect in these patients \[[@R32]\]. In multivariate analysis, a higher plasma cyclin D1 (*CCND1*; 11q13) to dopamine receptor D2 (*DRD2*; 11q22-23) ratio (C/D ratio) was significantly correlated with worse prognosis \[[@R33]\]. In another study, high concordance of multiple somatic mutations was found between plasma ctDNA and tumor (primary or metastases) DNA (83%--100%). The allele frequencies of the mutations increased with tumor burden and preceded radiologic evidence of tumor recurrence by 6 months \[[@R34]\].

In 29 patients with localized esophageal carcinoma treated with chemoradiotherapy, baseline ctDNA levels (NGS-based CAPP-seq) were correlated with metabolic tumor volume and squamous histology. The 2-year overall survival (OS) rates for pretreatment ctDNA-positive vs. ctDNA-negative patients were 47% and 86%, respectively (HR = 6.0; *p* \< 0.05). Compared to patients with undetectable ctDNA, detection of ctDNA post-treatment was predictive of shorter event-free survival (EFS, *p* \< 0.0001) and shorter time to distant metastasis (*p* \< 0.0001) \[[@R35]\].

### Gastric cancer {#s1_4_2}

ctDNA analysis is used to detect and monitor HER2 copy numbers in patients with gastric cancer \[[@R36]\]. The preoperative ratio of HER2 to RPPH1 (ddPCR) has been correlated with tumor HER2 status (*p* \< 0.001; sensitivity, 0.73; specificity, 0.93) \[[@R37]\].

In another study, the concordance rate of HER2 amplification detected between formalin-fixed, paraffin-embedded (FFPE) samples vs. ddPCR and immunohistochemical (IHC) analysis/fluorescence *in situ* hybridization (FISH) was 92%. The concordance rate of FFPE with ctDNA was 62.5%. HER2 positivity by ctDNA analysis was associated with significantly shorter OS compared to HER2 negativity \[[@R38]\]. In late-stage gastric cancer, ctDNA mutations were associated with poor prognosis \[[@R39]\].

In a multiple-parallel cohort, ctDNA-guided plasma-based digital sequencing in patients with metastatic solid tumors, including gastric cancer, identified somatic alterations in 78% of the 76 patients with gastric cancer, and 33% of these 76 patients had targetable alterations. Ten patients with gastric cancer received molecularly matched therapy, which resulted in response and disease control rates of 67% and 100%, respectively \[[@R40]\].

### Colorectal cancer {#s1_4_3}

In a prospective study of 106 patient samples of CRC, ctDNA analysis of *KRAS* and *BRAF* mutational status was compared to the analysis of tumor tissue \[[@R2]\]. The specificity and sensitivity of ctDNA were both 100% for *BRAF V600E* mutation and were 98% and 92%, respectively, for *KRAS* point mutations. Overall, ctDNA was detected in 100% of patients with metastatic CRC, suggesting that ctDNA analysis could replace tumor analysis in these patients \[[@R2]\].

ctDNA has been used to detect MRD in the adjuvant setting in stage II CRC \[[@R41], [@R42]\]. In a prospective study of 230 patients, \[[@R43]\] the recurrence rate among patients who did not receive adjuvant chemotherapy was 79% (11/14) in patients with detectable ctDNA vs. 9.8% (16/164) in patients with undetectable ctDNA (HR = 18; *p* \< 0.001). ctDNA detection after completion of chemotherapy was associated with shorter recurrence-free survival (HR = 11; *p* = 0.001) suggesting the presence of MRD \[[@R43]\].

The same investigators analyzed ctDNA in patients with stage III CRC post-operatively, during, and after adjuvant chemotherapy \[[@R44]\]. In 95 patients who received adjuvant chemotherapy, serial ctDNA analysis identified residual metastatic disease not evident on imaging studies \[[@R44]\].

In another longitudinal cohort study, ctDNA was used to monitor tumor burden in 21 CRC \[[@R45]\] patients with localized disease who had ctDNA analysis 3 months post-operatively; disease recurrence within 3 years occurred in all 6 patients with detectable ctDNA at 3 months compared to 27% (4/15) of those with undetectable ctDNA at 3 months (HR = 37.7; *p* \< 0.001). Of 18 patients who had surgical resection of liver metastases, ctDNA detection 3 months post-surgically predicted disease recurrence compared to patients with undetectable ctDNA and metastatic CRC (HR = 4.9; *p* = 0.007). Therefore, postoperative ctDNA detection identified patients at high risk of relapse \[[@R45]\].

### Pancreatic and biliary tract carcinomas {#s1_4_4}

The role of ctDNA is particularly important in patients with pancreatic and biliary tract carcinomas because biopsy samples are often inadequate for molecular profiling. In a prospective analysis in 26 patients with pancreatic (*n* = 18) or biliary (*n* = 8) cancer, tumor sequencing using a 54-gene panel failed in 9 patients (35%), and of the remaining 17 patients, 90.3% of the mutations detected in the tumor biopsies were also detected using ctDNA. The diagnostic accuracy of ctDNA sequencing was 97.7% (5 informative genes: sensitivity, 92.3%; specificity, 100%) \[[@R46]\].

In pancreatic cancer, high ctDNA levels of KRAS and/or other mutations have been associated with poor progression-free survival (PFS) and/or OS \[[@R47], [@R48]\]. However, low concordance between the blood and tissue samples has been reported in patients with pancreatic ductal adenocarcinoma \[[@R49]\].

In a prospective study in advanced pancreatic cancer, ctDNA was analyzed for *KRAS* mutations using blood samples collected prior to gemcitabine or FOLFIRINOX (5-fluorouracil, oxaliplatin, irinotecan, and leucovorin) treatment and monthly during treatment (median follow-up, 3.7 months). Disease progression was more frequent in patients with ctDNA-identified *KRAS* mutations at baseline compared to *KRAS*-mutant-negative patients (9/10 vs. 1/4; *p* = 0.01). The baseline ctDNA level was associated with PFS (*p* = 0.014) and OS (*p* = 0.01). ctDNA level changes were correlated with imaging studies and CA19-9 levels, indicating that ctDNA may be used to monitor disease activity in these patients \[[@R47]\]. In other studies, ctDNA analysis detected mutations in up to 48% of patients, and these mutations were associated with shorter OS. In another study, ctDNA analysis (ddPCR for rare *KRAS* mutations) detected mutations in 31% of 105 patients with pancreatic ductal adenocarcinoma who underwent pancreatoduodenectomy. Detectable ctDNA KRAS mutations were associated with shorter OS compared to patients without mutations (13.6 months vs. 27.6 months; *p* \< 0.0001) \[[@R48]\]. Other investigators using ctDNA analysis detected *KRAS* among other mutations (*TP53*, *SMAD4*, *STK11*, *PIK3CA*, *NRAS*) using ctDNA in 48% of patients with advanced pancreatic adenocarcinoma. These mutations were strongly correlated with shorter OS compared to OS of patients with undetectable mutations (6.5 vs. 19.0 months; *p* \< 0.001) \[[@R50]\].

ctDNA analysis is a promising prognostic marker in early-stage pancreatic cancer that could also help guide treatment after Whipple surgery \[[@R51]\]. ctDNA analysis of pre- and post-operative plasma samples and tumor tissue (*n* = 42) using PCR-based SafeSeqS assays to identify *KRAS* mutation (codons 12, 13, and 61) identified RAS mutations in 90.5% of tumor samples and in 62.2% of 37 pre-operative and 37.1% of 35 post-operative plasma samples. ctDNA detection was an independent factor predicting shorter recurrence-free survival compared to undetectable ctDNA preoperatively (10.3 months vs. not reached, HR = 3.4; *p* = 0.005) and postoperatively (5.4 months vs. 17.1 months, HR = 5.4; *p* \< 0.0001) \[[@R51]\].

In ctDNA promoter hypermethylation analysis of a selected gene panel, the number of methylated genes was significantly higher in patients with pancreatic adenocarcinoma than in healthy individuals or patients with acute pancreatitis (mean, 8.41 vs. 4.74, respectively; *p* \< 0.001), suggesting that ctDNA promoter hypermethylation may be used for diagnostic purposes in pancreatic adenocarcinoma \[[@R52]\].

ctDNA analysis can also inform the diagnosis, prognosis, and treatment of patients with biliary tract cancer. In patients with metastatic locally advanced/metastatic biliary tract cancer, the concordance rate between plasma ctDNA analysis and tumor tissue analysis (15-gene panel) was 74%; this rate was 92% in intrahepatic tumors. ctDNA variant allele frequency (VAF) was significantly correlated with tumor load and PFS, and the mutational profile changed after chemotherapy in 36% of patients \[[@R53]\].

### Hepatocellular carcinoma {#s1_4_5}

ctDNA analysis has been investigated in hepatocellular carcinoma (HCC) \[[@R54]--[@R56]\]. In patients who underwent hepatectomy or liver transplantation, disease recurrence and extrahepatic metastases were more frequent in those with mutations detected by ctDNA analysis vs. others (*p* = 0.01 and 0.04, respectively) and ctDNA was an independent factor predicting invasion of the portal vein (odds ratio = 6.10) \[[@R54]\]. In other studies, hotspot mutations in the *TERT*, *CTNNB1*, and *TP53* genes detected in the plasma of patients with HCC were associated with vascular invasion and likely predicted a shorter recurrence-free survival time \[[@R55]\].

### Breast cancer {#s1_4_6}

The concordance between ctDNA and tissue DNA in breast cancer varies by stage and subtype \[[@R57]\]. In patients with early-stage breast cancer, *PIK3CA* mutations have been identified presurgically in ctDNA with high sensitivity (93.3%) and specificity (100%) \[[@R58]\]. In a retrospective analysis, the concordance between tissue DNA and ctDNA (digital sequencing of plasma-derived DNA) was robust in *PIK3CA* mutation and ERBB2 amplification analyses (Cohen's κ = 0.64 and 0.77, respectively) but poor in *TP53* mutation and EGFR amplification analyses (Cohen's κ = 0.18 and 0.33, respectively) \[[@R59], [@R60]\]. In another study, *TP53* and *PIK3CA* mutant allele frequencies were associated with response to therapy and PFS \[[@R60]\]. When PCR and targeted exome sequencing were used to detect the hotspot *AKT1* E17K mutation in two cohorts of patients with advanced metastatic breast cancer (MBC), the concordance rates between tissue and blood samples were 98% and 97.1% \[[@R61]\].

ctDNA analysis has been used extensively in large trials in hormone-receptor--positive, HER2-negative advanced breast cancer. In the BOLERO-2 study, *PIK3CA* mutations by ctDNA analysis were associated with efficacy of everolimus \[[@R62], [@R63]\]. In the BELLE-3 study, patients progressing on or after mTOR inhibition and endocrine therapy \[[@R64]\] with *PIK3CA* mutations (detected by ctDNA or tissue DNA analysis; concordance, 80%) had significantly longer PFS in the buparlisib plus fulvestrant arm compared to the fulvestrant arm \[[@R64], [@R65]\].

In patients with HER2-positive breast cancer treated with an anti-HER1/HER2 tyrosine kinase inhibitor, ctDNA analysis for HER2 amplification was associated with disease progression (4/6, 66.7%), whereas *TP53* mutations (3/6, 50%) and PI3K/mTOR pathway alterations (3/6, 50.0%) were associated with disease resistance. Dynamic ctDNA analysis identified drug resistance with sensitivity 85.7% and specificity of 55.0%; and had a high concordance rate with CT imaging studies (82.1%) \[[@R66]\].

In patients with non-metastatic triple-negative breast cancer, ddPCR for customized ctDNA analysis detected alterations in 75% of patients at baseline. Lower ctDNA levels were associated with longer OS during neoadjuvant chemotherapy \[[@R67]\]. In this setting, targeted MRD sequencing using serial ctDNA monitoring predicted tumor recurrence 7.9 months (median) before clinical evidence of relapse \[[@R68]\].

Other investigators found that a panel of cell-free methylation markers was a strong predictor of OS in MBC and may have clinical usefulness in risk disease monitoring \[[@R69]\]. Methylated ctDNA from the promoter region of *RASSF1A* was more sensitive than carcinoembryonic antigen and CA15-3 for monitoring response to neoadjuvant chemotherapy \[[@R70]\]. ctDNA analysis of a 6-gene methylation panel for diagnosis of breast cancer had sensitivity of 79.6% compared to healthy individuals and 82.4% compared to benign disease control (specificity, 72.4% and 78.1%, respectively). This test complemented mammography or ultrasonography \[[@R71]\].

ctDNA for assessment of resistance to aromatase inhibitors as first-line therapy was also prospectively studied in MBC (*n* = 83) \[[@R72]\]. *ESR1* mutations were detected in 56.4% (22/39) of patients who had disease progression 6.7 months (median) prior to clinical progression \[[@R72]\]. On the basis of detection of *ESR1* mutations in primary breast cancer using ctDNA analysis at a very low allele frequency, in contrast to a high allele frequency in metastases, it is plausible that in some tumors rare *ESR1*-mutant clones may be enriched by endocrine therapy \[[@R73]\].

### Gynecologic cancers {#s1_4_7}

ctDNA analysis has contributed to diagnosis and monitoring of patients with gynecologic cancers. High ctDNA levels have been associated with poor PFS and OS in patients with resistant epithelial ovarian cancer treated with bevacizumab (*n* = 144) \[[@R74]\]. In patients with high-grade serous ovarian carcinoma who received standard-of-care therapy, p53 alterations identified using ctDNA analysis at baseline were correlated with volume of disease, and a decrease in *TP53* mutant allele fraction ≤60% after 1 cycle of chemotherapy was associated with shorter time to disease progression \[[@R75]\].

In patients with gynecologic cancer (*n* = 44), ctDNA analysis using ddPCR detected alterations in 93.8% of patients, and detected cancer in 6 patients, 7 months prior to radiologic evidence on CT imaging studies \[[@R76]\]. ctDNA levels were correlated with serum CA-125 levels and CT imaging studies, and they were an independent factor predicting OS \[[@R76]\].

Plasma DNA analysis for detection of chromosomal instability using copy-number alterations in patients with an adnexal mass (*n* = 68) and in healthy individuals (*n* = 44) improved detection of malignancy (AUC = 0.89) compared to serum CA-125 (AUC = 0.78) or the RMI (risk of malignancy) index (composite of serum CA 125 level, ultrasound scan result and menopausal status) (AUC = 0.81) \[[@R77]\].

Data suggest that human papillomavirus (HPV) detection by ctDNA analysis is a surrogate marker for HPV-associated cervical cancer and can guide antiviral therapy. In patients with HPV 16/18-associated cervical cancer and tumors \>2 cm at diagnosis, HPV ctDNA was identified in 11 of 13 patients and levels were associated with tumor dynamics \[[@R78]\]. In another study, HPV ctDNA was detected in all patients (*n* = 19) with HPV-positive metastatic cervical cancer but in 0 healthy blood donors (*n* = 45) \[[@R79]\]. Of 9 patients who received tumor-infiltrating lymphocyte (TIL) immunotherapy, the HPV genotype of the patients' tumors was identified in serum samples from all patients, and 2 patients with complete response had persistent clearance of HPV ctDNA \[[@R79]\].

Genitourinary cancers {#s1_5}
---------------------

### Prostate cancer {#s1_5_1}

In patients with metastatic castration-resistant prostate cancer (mCRPC), ctDNA analysis can identify molecular alterations that are associated with clinical outcomes and can guide therapy. Detection of biallelic *BRCA2* gene loss by ctDNA analysis indicated that patients may benefit from therapies targeting defective DNA repair \[[@R80]\]. Others identified alterations in all analyzed patients with mCRPC treated with enzalutamide, including alterations in DNA damage repair and PI3K pathway genes \[[@R81]\]. Aberrations in the androgen receptor (*AR*) gene by ctDNA analysis have been correlated with resistance to enzalutamide and abiraterone treatment and *AR* amplification was more common in patients whose disease progressed on enzalutamide compared to abiraterone or other agents (*p* = 0.02) \[[@R82]\]. Targeted NGS covering all AR coding bases using plasma from patients treated with abiraterone (control, patients' normal circulating DNA) identified AR copy numbers in 82.5% (80/97) of patients and demonstrated that 45% of tumors had AR gain or T878A or L702H changes before abiraterone treatment, which were associated with shorter PFS and OS \[[@R83]\]. Other investigators also demonstrated that circulating AR copy number gain is a useful biomarker \[[@R84]\]. In patients with CRPC treated with docetaxel followed by enzalutamide (*n* = 59), patients with AR copy number gain (36%) had higher levels of PSA, alkaline phosphatase, and lactate dehydrogenase (LDH) and shorter PFS (*p* = 0.0004) and OS (*p* = 0.0003) compared to those without AR copy number gain. In multivariate analysis, a decrease in PSA ≥50% and AR copy number gain were associated with longer PFS and OS \[[@R84]\].

In a retrospective study, ctDNA genomic profiling using Guardant 360™ demonstrated ≥1 alteration in 94% of 514 men with progressive mCRPC, and had good concordance with the correspondent tumor tissue \[[@R85]\]. Higher numbers of ctDNA alterations were associated with shorter time to treatment failure (HR = 1.05, *p* = 0.026) in patients treated with chemotherapy or androgen inhibitors \[[@R85]\].

### Renal cell carcinoma {#s1_5_2}

Total serum ctDNA levels and CpG island methylation of *RASSF1A* and *VHL* were shown to support the diagnosis of renal cell carcinoma (RCC) and VHL methylation indicates clear cell RCC \[[@R86]\]. Higher levels of ctDNA were identified in metastatic RCC or necrotic RCC compared to benign tumors, and they were associated with poorer DFS \[[@R86]\]. Using Guardant 360 ctDNA analysis, 78.6% of 220 patients with RCC had \>1 alteration and the most frequent alterations were TP53 (35%), VHL (23%), EGFR (17%), NF1 (16%), and ARID1A (12%) \[[@R87]\]. Higher rates of detection after systemic therapy compared with baseline were noted for *NF1* (21% vs. 3%), *TP53* (49% vs. 24%), and *VHL* (29% vs. 18%), indicating clonal evolution of genomic alterations \[[@R87]\].

### Bladder cancer {#s1_5_3}

In patients with advanced urothelial carcinoma, high rates (86%--90%) of aberrations using Guardant 360 ctDNA analysis were found; the most common aberrations were *TP53* (48%), *ARID1A* (17%), and *PIK3CA* (14%) \[[@R88], [@R89]\]. Using a 62-gene panel (FoundationACT), 73% of patients with metastatic urothelial cancer were found to have ≥1 aberration and the most frequent alterations were *TP53* (68%) and *TERT*-promoter (38%) \[[@R90]\]. In another study, 36% (129/363) of patients with non-muscle-invasive bladder cancer and 11% (44/403) of patients with muscle-invasive bladder cancer who underwent radical cystectomy had ≥1 *FGFR3* or *PIK3CA* mutations and high ctDNA levels were associated with disease progression. ctDNA levels in the urine and plasma were positively correlated and indicated that higher levels of *FGFR3-* and *PIK3CA*-mutated DNA can predict disease progression \[[@R91]\].

### Melanoma {#s1_5_4}

In patients with metastatic melanoma, identification of *BRAF* mutations in ctDNA has been associated with higher disease burden and worse prognosis and may precede clinical evidence of disease progression. In patients with unresectable advanced-stage metastatic melanoma, *BRAF* and *NRAS* mutations identified in ctDNA analysis at baseline and during treatment with targeted therapy against BRAF or immunotherapy have been associated with larger tumors, increased LDH levels, and brain metastases \[[@R92]\]. Other investigators found that in this setting, the presence of BRAF mutations in ctDNA analysis was associated with a higher number of metastatic sites, higher serum LDH levels or S100 protein concentration, and shorter OS \[[@R93]\].

In one study, 73% of 48 patients with metastatic melanoma had tumor-associated *BRAF* and *NRAS* alterations in ctDNA analysis \[[@R94]\]. In another study, patients with the BRAF V600E mutation in ctDNA had shorter PFS and OS compared to those without the mutation (*p* = 0.02 and *p* = 0.017, respectively) \[[@R95]\]. Others also demonstrated that lower baseline ctDNA levels were associated with higher rates of response and PFS \[[@R94]\]. In patients with BRAF V600E/V600K-positive tumors enrolled in 4 different studies of dabrafenib or trametinib, ctDNA analysis identified BRAF V600E and BRAF V600K mutations in 76% and 81% of 732 patients, respectively. Patients with undetectable ctDNA *BRAF* mutations at baseline had higher rates of response, PFS, and OS than those with ctDNA BRAF mutations \[[@R96]\]. Circulating BRAF mutations have been identified in some patients prior to clinical evidence of disease progression \[[@R97]\]. In patients with melanoma who received adoptive transfer of activated autologous TILs, ctDNA analysis for BRAF V600E (*n* = 48, 388 serum samples) demonstrated a strong correlation between an early peak of circulating V600E mutation and objective response. Patients whose serum had an early ctDNA peak followed by undetectable ctDNA had a higher likelihood of having a complete response in 1--2 years \[[@R97]\]. Others also found a correlation between serial ctDNA analysis of *BRAF* and *NRAS* status and tumor response. PFS was longer in patients with an early decrease (1--4 weeks post-treatment) in ctDNA levels than in patients with unchanged or increased ctDNA levels post-treatment (HR = 2.6; *p* = 0.05) \[[@R98]\]. In the post-surgical setting, ctDNA analysis of *BRAF* and *NRAS* mutations predicted OS in 161 patients with high-risk stage II/III melanoma who underwent surgical resection followed by adjuvant bevacizumab for 1 year \[[@R99]\]. The 5-year OS rates were 33% and 65% for patients with detectable and undetectable ctDNA levels, respectively. After adjustment for performance status, patients with detectable ctDNA had shorter OS compared to those with undetectable ctDNA (HR = 2.63; *p* = 0.003) \[[@R99]\].

An intriguing application of longitudinal ctDNA analysis is the distinction of pseudoprogression from true progression \[[@R100]\]. ctDNA for BRAF and NRAS mutations was analyzed at baseline and at 12 weeks of treatment with PD-1 antibodies with or without ipilimumab \[[@R100]\]. Overall, 23.2% (29/125) of patients had initial disease progression by imaging studies. Thirty-one percent (9/29) of patients had pseudoprogression and 69% (20/29) had true progression. The 9 patients with confirmed pseudoprogression had undetectable ctDNA at baseline or detectable ctDNA at baseline followed by \>10-fold decrease (favorable ctDNA profile). Eighteen of 20 patients with true progression had detectable ctDNA at baseline that remained stable or increased (unfavorable ctDNA profile). Among patients with confirmed true progression, the 1-year OS rates were 82% and 39% in those with favorable ctDNA and unfavorable ctDNA profiles, respectively (HR = 4.8; *p* = 0.02) \[[@R100]\].

Sarcoma {#s1_6}
-------

### Ewing sarcoma {#s1_6_1}

In patients with localized or metastatic Ewing sarcoma (EWS), copy numbers of the EWSR1 fusion sequence in plasma were associated with tumor volume. Rapid decrease in ctDNA levels of EWSR1 was noted during initial chemotherapy, and increase in ctDNA levels indicated disease recurrence \[[@R101]\]. As a driving EWS-ETS translocation specific to each tumor is identified in up to 95% of patients with Ewing sarcoma, investigators used long-range PCR analysis to identify tumor-specific EWS-ETS breakpoints in plasma DNA \[[@R102]\]. In children with metastatic Ewing sarcoma and primary localized osteosarcoma, detection of ctDNA was associated with inferior outcomes \[[@R103]\]. In patients with localized EWS and detectable ctDNA, the 3-year rates of EFS and OS were lower compared to those with undetectable ctDNA (*p* = 0.006 and *p* = .01, respectively). The respective rates in localized osteosarcoma for EFS were 48.6% vs. 82.1% (*p* = 0.006) and for OS were 79.8% vs. 92.6% (*p* = 0.01); the risk of death increased proportionately with ctDNA levels \[[@R103]\].

### Gastrointestinal stromal tumors {#s1_6_2}

In patients with gastrointestinal stromal tumors (GIST), ctDNA harboring *CKIT* or *PDGFRA* was used as a tumor-specific biomarker and the amount of mutant-free circulating DNA was correlated with disease course \[[@R104]\]. In patients with TKI-refractory GIST treated with dovitinib, genotyping of the KIT gene in exon 17 of serum ctDNA using beads, emulsions, amplification, and magnetics assays identified mutations associated with disease resistance \[[@R105]\]. Other investigators suggested that detection of secondary *C-KIT* mutations in ctDNA may improve the selection of targeted agents \[[@R106]\].

### Soft tissue sarcoma {#s1_6_3}

In patients with metastatic soft tissue sarcoma, ctDNA was detected in 36% (4/11) of patients and TP53/PIK3CA mutations in ctDNA analysis were concordant with the primary tumor in 2 of 4 patients \[[@R107]\].

### Brain tumors {#s1_6_4}

In brain tumors, ctDNA analysis is used as a non-invasive alternative to tumor biopsies that are associated with significant risk. In patients with glioblastoma multiforme (GBM), ctDNA analysis identified the EGFRvIII deletion in 3 of 13 patients, which was correlated with tumor tissue analysis \[[@R108]\]. This mutation is identified in approximately one third of patients with GBM and is associated with resistance to chemotherapy and radiotherapy. ctDNA levels were correlated with the extent of tumor resection. This test may help select patients for anti-EGFRvIII therapy and monitor response to treatment \[[@R108]\]. In patients with neuroblastoma, serum MYCN amplification (real-time quantitative PCR, sensitivity 86%, specificity 95% compared with tissue analysis) was associated with OS, suggesting that it may help select treatment prior to tumor biopsy, particularly for patients younger than 18 months whose risk assessment and treatment depend on MYCN amplification status \[[@R109]\]. In patients with glioma, the *IDH1* R132H mutation was identified in plasma with a specificity of 100% and sensitivity related to the tumor volume and contrast enhancement, suggesting that it may help in the diagnosis of patients not amenable to biopsy \[[@R110]\].

Lymphoma {#s1_7}
--------

### Classical Hodgkin lymphoma {#s1_7_1}

In patients with classical Hodgkin lymphoma, an *XPO1* mutation detected using ctDNA analysis at the end of treatment was associated with a tendency toward shorter PFS compared to patients without the mutation, suggesting that plasma ctDNA may be clinically useful for the noninvasive management of this disease \[[@R111]\].

### Diffuse large B-cell lymphoma {#s1_7_2}

In patients with relapsed, refractory *de novo*, or transformed diffuse large B-cell lymphoma (DLBCL) treated with panobinostat with or without rituximab, ctDNA was detected in ≥1 plasma sample in 96% of the patients and its increase was associated with resistance to treatment \[[@R112]\]. In another study of patients with lymphoma and healthy subjects, the amount of ctDNA at diagnosis was strongly correlated with clinical indices and was independently predictive of patient outcomes \[[@R113]\]. ctDNA genotyping could help distinguish indolent follicular lymphomas from those that transformed into DLBCL and classify transcriptionally defined tumor subtypes, including DLBCL cell of origin \[[@R113]\].

Other investigators used immunoglobulin high-throughput sequencing (Ig-HTS) \[[@R114]\] to analyze circulating leukocytes and ctDNA of patients with DLBCL. At baseline, Ig clonal rearrangement was detected in 82% and 71% of patients in ctDNA and circulating cells, respectively (*p* = 0.68); at relapse, the respective rates were 100% and 30% (*p* = 0.001). Interestingly, Ig-HTS detection preceded radiologic evidence of recurrent disease by 88 days with high sensitivity and specificity, indicating that it may be a surrogate marker for monitoring disease after complete remission is achieved \[[@R114]\].

In a retrospective study in patients with DLBCL after first-line treatment, disease progression was evident on imaging studies a median of 3.5 months (range, 0-200 months) after detection on ctDNA analysis of the clonal Ig gene sequence \[[@R115]\].

In contrast to these data showing that ctDNA is associated with prognosis and can be identified prior to radiologic evidence of recurrent DLBCL, in patients with newly diagnosed primary central nervous system lymphoma who had 34-gene panel high-throughput sequencing of primary tumors followed by targeted sequencing of identified somatic mutations on plasma, the correlation between ctDNA concentration and tumor volume was insignificant (R^2^ coefficient = 0.01) \[[@R116]\]. Overall, 88% of patients with MYD88 L265P in tissue had an identifiable L265P variant in their ctDNA and OS was not significantly correlated with mutations detected in ctDNA \[[@R116]\].

### Clinical trials across tumor types {#s1_7_3}

In patients with advanced cancer, circulating nucleic acid biomarker analyses had promising clinically important multipurpose utility awaiting further studies \[[@R117]\]. In an analysis of 105 patients using the Sequenom MassArray System and OncoCarta panel for somatic mutations, the ctDNA concentration was 3 times higher in patients with advanced cancer compared to healthy volunteers. Although the concordance between matched ctDNA and archival tumor tissue was high for selected 'hot-spot' mutations (*KRAS*, *BRAF*, *PIK3CA*), some differences were noted between archival tumor and ctDNA. Factors predicting longer OS in multivariate analysis were lower ctDNA concentration, higher albumin levels, and better performance status \[[@R117]\].

We have previously published our experience analyzing ctDNA and archival primary or metastatic tumor tissue (FFPE) from patients with advanced metastatic cancer who were referred to our Phase I program at MD Anderson for participation in clinical trials \[[@R118]\]. We found that the concordance rates between mutations in archival tissue and ctDNA were high in patients with refractory cancer types that progressed on systemic therapy. These rates were 91%, 99%, 83%, and 91% for BRAF, EGFR, KRAS, and PIK3CA mutations, respectively \[[@R118]\]. Patients with \>1% of KRAS mutant ctDNA had shorter OS compared to those with ≤1% of KRAS mutant ctDNA (4.8 vs. 7.3 months, *p* = 0.008). Patients with \>1% of mutant ctDNA (BRAF, EGFR, KRAS, or PIK3CA) had shorter OS compared to those with ≤1% of mutant ctDNA (5.5 vs. 9.8 months, *p* = 0.001) \[[@R118]\].

Other investigators demonstrated that ctDNA and circulating tumor cells are distinct biomarkers, as ctDNA was also detected in patients without any evident circulating tumor cells \[[@R119]\]. ctDNA analysis demonstrated high detection rates (\>75%) in advanced breast, bladder, colorectal, gastroesophageal, hepatocellular, head and neck, melanoma, ovarian, and pancreatic cancer. Low detection rates (\<50%) were noted in primary brain, renal, prostate, and thyroid cancers. In localized tumor stage, the rate of ctDNA detection was 73% in CRC, 57% in gastroesophageal, and 50% in breast adenocarcinoma. In metastatic CRC (*n* = 206), ctDNA analysis for KRAS mutation was associated with high sensitivity (87.2%) and specificity (99.2%). ctDNA analysis to assess resistance mechanisms to anti-EGFR treatment in patients with CRC demonstrated that 96% (23/24) of patients developed ≥1 mutation in genes involved in the mitogen-activated protein kinase pathway \[[@R119]\].

In a study of clonal evolution, exome sequencing of ctDNA using serial plasma from 6 patients with breast, ovarian, or lung cancer demonstrated that emergence of resistance was associated with increased mutant allele fractions, and an activating *PIK3CA* mutation was noted after treatment with paclitaxel \[[@R120]\]. In another study with ctDNA analysis of 23 patients with various tumor types treated with PI3K-AKT-mTOR pathway or MEK inhibitors, clonal response to treatment was noted and some clones changed over time discordantly. Increasing mutational levels were associated with poorer prognosis \[[@R121]\].

Other investigators used NGS to analyze 54 genes and copy number variants in three genes (EGFR, ERBB2 and MET) on ctDNA of patients with various tumor types \[[@R122]\]. Overall, 171 patients with lung (*n* = 39), breast (*n* = 39), glioblastoma (*n* = 33), or other cancers were analyzed. Actionable mutations were noted in 40% (TP53 29.8%, EGFR 17.5%, MET 10.5%, PIK3CA 7%, and NOTCH1 5.8%). Eighteen percent (6/33) of patients with glioblastoma had actionable mutations \[[@R122]\]. The same investigators analyzed 168 patients with diverse cancers \[[@R123]\]. In ctDNA analysis, 58% of patients had ≥1 alteration. Among them, 71.4% had ≥1 alteration potentially targeted by an FDA-approved drug. The concordance rates between ctDNA analysis and tissue analysis were: TP53 70.3%, EGFR 70.3%, PIK3CA 88.1%, and ERBB2, 93.1%. In patients with ≥1 alteration, those with ctDNA ≥5% of total DNA had shorter OS compared to patients with ctDNA \<5% (median, 4.03 months vs. NR, *p* \< .001) \[[@R123]\]. With the use of checkpoint inhibitor--based immunotherapy across various histologies, correlation between high alteration number detected in blood-derived ctDNA and favorable response, PFS and OS has been reported \[[@R124]\].

In a meta-analysis of patients with solid tumors (39 studies, 4,052 patients), detection of ctDNA in plasma was associated with shorter OS in multivariable analyses \[HR, 2.70; *P* \< .001) compared to patients with undetectable ctDNA \[[@R125]\].

Selected studies by tumor type, the gene (s) used for ctDNA analysis, and outcomes are summarized in [Table 1](#T1){ref-type="table"}.

###### Selected studies by tumor type, the gene(s) used for ctDNA analysis, and outcomes

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Year, First\                   Study Type         Tumor Type             Number\            Biomarker\                     Tested Genes                           Outcome
  Author \[Ref\]                                                           of Patients        Method                                                                
  ------------------------------ ------------------ ---------------------- ------------------ ------------------------------ -------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Lung cancer**                                                                                                                                                   

  2016, Adrian G.\               Prospective        Advanced NSCLC         180                ddPCR                          *KRAS, EGFR*                           Detection of KRAS and EGFR mutations, lower turnaround time compared to tissue
  Sacher \[[@R8]\]                                                                                                                                                  

  2016, Jeffrey C.\              Cohort             Advanced NSCLC         102                Hybrid capture NGS             70 cancer-related genes                Detection of potentially actionable variants in 75% of patients; concordance with tissue, 79%
  Thompson \[[@R10]\]                                                                                                                                               

  2018, Nicolas\                 Cohort, blinded\   Advanced NSCLC         168 specimens\     Amplicon-based NGS             36 cancer-related genes                Detection of EGFR mutations, rare variants and fusions with high specificity. Early detection of resistance mechanisms in serial samples.
  Guibert \[[@R13]\]             to tissue                                 from 46 patients                                                                         

  2018, Charu\                   Prospective        Advanced NSCLC         323                Hybrid capture                 73 cancer-related genes                Detection of actionable alterations in 20% of stage IV M1b patients in plasma but not tissue. Complementarity of tissue and plasma
  Aggarwal \[[@R20]\]                                                                                                                                               

  2014, Aaron M.\                Cohort             Early-stage lung\      103                Hybrid capture                 16 cancer-related genes + 8 proteins   Detection of ctDNA in early stages (stage I sensitivity, 50%)
  Newman \[[@R25]\]                                 cancer                                                                                                          

  2017, Christopher\             Cohorts            Early-stage lung\      96                 Patient-specific\              10--22 SNVs                            MRD and subclonal evolution
  Abbosh \[[@R26]\]                                 cancer                                    multiplex PCR                                                         

  **Gastro-intestinal tumors**                                                                                                                                      

  2016, Honglei\                 Cohort             Esophageal, SCC        8                  Illumina TruSight\             90 cancer-related genes                Multigene panel has a role in detection and monitoring response to treatment
  Luo \[[@R32]\]                                                                              sequencing                                                            

  2010, Hiroki\                  Case-control       Esophageal, SCC        96 patients,\      PCR-applied\                   *CCND1* amplification                  Poor prognostic value of CCND1 amplification
  Takeshita \[[@R33]\]                                                     40 controls        biosystems                                                            

  2016, Masami\                  Cohort             Esophageal, SCC        13                 HiSeq2000                      53 cancer-related genes                Multigene panel is associated with a greater accuracy of tumor recurrence compared to imaging methods (post-op)
  Ueda \[[@R34]\]                                                                                                                                                   

  2015, Katsutoshi\              Case-control       Gastric                52 patients,\      PCR-applied\                   *HER-2*                                HER2 amplification can be used for therapeutic monitoring
  Shoda \[[@R36]\]                                                         40 controls        biosystems                                                            

  2017, Katsutoshi\              Case-control       Gastric                60 patients,\      PCR-applied\                   *HER-2*                                HER2 amplification can be used for therapeutic monitoring
  Shoda \[[@R37]\]                                                         30 controls        biosystems                                                            

  2015, Hideaki\                 Cohort             Gastric                25                 PCR - QX200, Bio-Rad           *HER-2*                                High concordance in detection of HER-2 between ddPCR and tissue IHC/FISH
  Kinugasa \[[@R38]\]                                                                                                                                               

  2016, Wen-Liang\               Cohort             Gastric                277                TaqMan qPCR                    68 mutations (8 genes)                 High ctDNA levels are associated with peritoneal recurrence and poor prognosis
  Fang \[[@R39]\]                                                                                                                                                   

  2017, Jeanne\                  Prospective,\      Colon                  230 (1046\         Safe-SeqS PCR                  15 cancer-related genes                ctDNA detection after stage II colon cancer resection provides direct evidence of residual disease and identifies patients at very high risk of recurrence.
  Tie \[[@R43]\]                 cohort,\                                  plasma samples)                                                                          
                                 multicenter                                                                                                                        

  2018, Jeanne\                  Prospective,\      Colon                  95                 Safe-SeqS PCR                  15 cancer-related genes                ctDNA detection after adjuvant chemotherapy for stage III colon cancer resection can identify patients at very high risk of recurrence.
  Tie \[[@R44]\]                 cohort,\                                                                                                                           
                                 multicenter                                                                                                                        

  2017, Lone V.\                 Longitudinal\      Colon                  45 (371\           QX200 PCR                      Somatic structural variants, *KRAS*    Postoperative ctDNA analysis detects residual disease and identifies patients at very high risk of relapse. Longitudinal surveillance allows\
  Schøler \[[@R45]\]             cohort                                    plasma samples)                                                                          early detection of relapse and response to intervention.

  2015, Oliver A.\               Cohort             Pancreato-biliary\     26                 Illumina Hi-Seq\               54 cancer-related genes                ctDNA sequencing is feasible, accurate, and sensitive in identifying tumor-derived mutations.
  Zill \[[@R46]\]                                   carcinomas                                2500                                                                  

  2016, Kjersti\                 Cohort             Pancreatic             14 (53\            Mx3000P rtPCR                  *KRAS*                                 ctDNA can be used as a marker for monitoring treatment efficacy and disease progression.
  Tjensvoll \[[@R47]\]                                                     plasma samples)                                                                          

  2016, Naoto\                   Cohort             Pancreatic             105                TaqMan assay PCR               *KRAS*                                 ctDNA can predict poor survival
  Hadano \[[@R48]\]                                                                                                                                                 

  2017, Daniel\                  Prospective,\      Pancreatic             135                Ion AmpliSeq NGS               112 cancer-related genes               ctDNA is an independent prognostic marker in advanced pancreatic adenocarcinoma
  Pietrasz \[[@R50]\]            cohort                                                                                                                             

  2018, Belinda\                 Cohort             Pancreatic             42                 SafeSeqS assays\               *KRAS*                                 ctDNA analysis is a promising prognostic marker in early-stage pancreatic cancer and guides risk-adaptive treatment strategies. ctDNA detection\
  Lee \[[@R51]\]                                                                              PCR                                                                   post-operatively helps to identify disease progression after standard adjuvant chemotherapy.

  2016, Stine Dam\               Prospective\       Pancreatic             95 patients,\      Methylation-specific\          28 cancer-related genes                ctDNA promoter hypermethylation is a diagnostic biomarker that helps distinguish malignant from benign pancreatic disease.
  Henriksen \[[@R52]\]           case-control                              183 controls       PCR                                                                   

  2018, Andreas\                 Cohort             Biliary tract cancer   24                 1010× depth Sequencing         15 cancer-related genes                The molecular landscape is represented in ctDNA.
  Wolfgang Berger \[[@R53]\]                                                                                                                                        

  2015, Atsushi\                 Cohort             Hepatocellular\        46                 Illumina Hi-Seq\                                                      ctDNA detection post-surgery reflects tumor progression and disease recurrence.
  Ono \[[@R54]\]                                    carcinoma                                 2500                                                                  

  2016, Wenjun\                  Cohort             Hepatocellular\        41                 Illumina MiSeq™                Cancer-related\                        ctDNA mutation detection is associated with vascular invasion and predicts a shorter recurrence-free survival time.
  Liao \[[@R55]\]                                   carcinoma                                                                genes TERT,\                           
                                                                                                                             TP53, and CTNNB1                       

  2016, Ao\                      Cohort             Hepatocellular\        48                 QX200 PCR                      Cancer-related\                        ctDNA analysis can detect intratumoral heterogeneity and may have a promising role in the therapeutic management.
  Huang \[[@R56]\]                                  carcinoma                                                                genes TERT,\                           
                                                                                                                             TP53, and CTNNB1                       

  **Breast cancer**                                                                                                                                                 

  2017, Heather A.\              Prospective\       Triple-negative\       26                 HiSeq 2500 Illumina            33 cancer-related genes                High concordance between ctDNA analysis and tumor tissue analysis, allowing monitoring of the therapeutic effect.
  Parsons \[[@R57]\]             cohort             breast cancer                                                                                                   

  2014, Julia A.\                Prospective\       Breast cancer          29                 ddPCR                          PIK3CA mutations                       In patients with early-stage breast cancer, mutations can be detected in tumor tissue using ddPCR, and ctDNA can be detected in blood before\
  Beaver \[[@R58]\]              cohort                                                                                                                             and after surgery.

  2016, Diana H.\                Retrospective\     Breast cancer          100                Illumina Hi-Seq 2500           TP53, PIK3CA,\                         Robust concordance between tissue and blood for detection of PIK3CA mutation and ERBB2 amplification, but not for TP53 mutation and\
  Liang \[[@R60]\]               chart review                                                                                ERBB2, and EGFR\                       EGFR amplification. Directional changes of TP53 and PIK3CA mutant allele are associated with response to therapy and PFS.
                                                                                                                             genomic alterations                    

  2016, Marion\                  Cohort             Breast cancer          600                HiSeq 2500 Illumina            306 cancer-related genes               AKT1E17K is the most likely disease driver in selected breast cancer patients and its detection in blood is achievable in advanced-stage disease.
  Rudolph \[[@R61]\]                                                                                                                                                

  2017, Mary Ellen\              Prospective        Breast cancer          724                QX200 PCR                      PIK3CA                                 Improvement in PFS was maintained using everolimus, irrespective of PIK3CA genotypes (detected by ctDNA), and it was consistent with\
  Moynahan \[[@R62]\]                                                                                                                                               previous analysis of archival tumor DNA using NGS.

  2016, Sarat\                   Prospective        Breast cancer          541                QX200 PCR                      ESR1                                   ESR1 mutations are prevalent in ER-positive metastatic breast cancer treated with aromatase inhibitors. Both Y537S and D538G mutations\
  Chandarlapaty \[[@R63]\]                                                                                                                                          are associated with aggressive disease biology.

  2018, Rosaria\                 Cohort             Breast cancer          3                  QX200 PCR                      *RB1*                                  Somatic RB1 mutations can emerge after exposure to CDK4/6 inhibitors.
  Condorelli \[[@R65]\]                                                                                                                                             

  2016, Fei\                     Prospective,\      Breast cancer          18                 HiSeq 2500 Illumina            368 cancer-related genes               ctDNA analysis provides information regarding resistance to treatment and guides administration of anti-HER2 targeted therapy in the metastatic setting.
  Ma \[[@R66]\]                  cohort                                                                                                                             

  2017, Francesca\               Cohort             Triple-negative\       46                 Illumina MiSeq                 *TP53*                                 ctDNA levels decreased quickly during neoadjuvant chemotherapy (NCT) and helped identify minimal residual disease after surgery. Slow\
  Riva \[[@R67]\]                                   breast cancer                                                                                                   decrease of ctDNA levels during NCT was strongly associated with shorter survival.

  2015, Isaac\                   Prospective,\      Breast cancer          55                 HiSeq 2500 Illumina            Cancer-related genes                   In patients with early stage breast cancer, ctDNA analysis can identify patients at high risk for relapse and guide adjuvant therapy.
  Garcia-Murillas \[[@R68]\]     cohort                                                                                                                             

  2017, Kala\                    Cohort             Breast cancer          141                cMethDNA assay                 10 cancer-related genes                ctDNA gene methylation is a strong predictor of survival outcomes.
  Visvanathan \[[@R69]\]                                                                                                                                            

  2017, Hiroyo\                  Cohort             Breast cancer          87                 Methylation-specific PCR       RASSF1A                                Met-ctDNA is a more sensitive marker than CEA and CA15-3 and it can be used to monitor clinical tumor response to neoadjuvant chemotherapy.
  Takahashi \[[@R70]\]                                                                                                                                              

  2016, Ming\                    Cohort             Breast cancer          749                MethyLight                     SFN, P16,\                             Epigenetic markers in serum have potential for diagnosis of breast cancer.
  Shan \[[@R71]\]                                                                                                            hMLH1, HOXD13,\                        
                                                                                                                             PCDHGB7 and RASSF1a                    

  2018, Charlotte\               Prospective,\      Breast cancer          83                 Enhanced\                      *ESR1, KRAS, NRAS* and *HRAS*          In patients with progressive disease after first-line aromatase inhibitors, ctDNA analysis demonstrated high levels of genetic heterogeneity and\
  Fribbens \[[@R72]\]            cohort                                                       tagged-amplicon\                                                      frequent sub-clonal mutations. Sub-clonal KRAS mutations were found at a high frequency.
                                                                                              sequencing (eTAm-Seq)                                                 

  2016, Peilu\                   Cohort             Breast cancer          126                Bio-Rad QX100 dd PCR           ESR1                                   *ESR1* mutations were detected at very low allele frequencies in some primary breast cancers, and at high allele frequency in patients with\
  Wang \[[@R73]\]                                                                                                                                                   metastatic breast cancer. *ESR1*-mutant clones are enriched by endocrine therapy.

  **Gynecological cancers**                                                                                                                                         

  2014, Karina Dahl\             Cohort             Ovarian cancer         144                QiaSymphony, multiplex qPCR    ctDNA detection                        In patients treated with bevacizumab, high ctDNA levels were associated with poor PFS and OS.
  Steffensen \[[@R74]\]                                                                                                                                             

  2016, Christine A.\            Retrospective\     Ovarian cancer         40                 ddPCR                          *TP53*                                 ctDNA is correlated with volume of disease at the start of treatment.
  Parkinson \[[@R75]\]           analysis                                                                                                                           

  2015, Elena\                   Cohort             Ovarian/\              44                 qPCR using TaqMan^®^, ddPCR    ctDNA detection                        ctDNA is an independent predictor of survival in patients with ovarian and endometrial cancers.
  Pereira \[[@R76]\]                                endometrial cancer                                                                                              

  2017, Adriaan\                 Prospective,\      Ovarian cancer         68                 HiSeq 2500 Illumina            Chromosome instability                 ctDNA analysis demonstrated that chromosomal instability can help detect ovarian cancer.
  Vanderstichele \[[@R77]\]      cohort                                                                                                                             

  2012, Maura\                   Cohort             Cervical cancer        16                 RT-qPCR                        ctDNA detection                        ctDNA analysis demonstrated that the HPV mutational insertion is a highly specific molecular marker and it is detected in most patients with\
  Campitelli \[[@R78]\]                                                                                                                                             stage 2-4 cervical cancer.

  2017, Zhigang\                 Retrospective\     Cervical cancer        19                 ddPCR                          HPV genetic components                 HPV genetic insertion in ctDNA represents a promising tumor marker.
  Kang \[[@R79]\]                analysis                                                                                                                           

  **Urological cancers**                                                                                                                                            

  2017, Matti\                   Prospective,\      Prostate cancer        319                NimbleGenSeqCap, Illumina      73 cancer-related genes                Biallelic gene loss detected in ctDNA can help prioritize therapy.
  Annala \[[@R80]\]              cohort                                                                                                                             

  2016, Alexander W.\            Cohort             Prostate cancer        65                 Illumina MiSeq, Ion Ampliseq   19 cancer-related genes                Genomic profiling of ctDNA is feasible in mCRPC patients and provides important insights into enzalutamide response and resistance.
  Wyatt \[[@R81]\]                                                                                                                                                  

  2015, Arun A.\                 Cohort             Prostate cancer        62                 PCR-based BEAMing              AR                                     AR gene aberrations in ctDNA are associated with resistance to enzalutamide and abiraterone in mCRPC.
  Azad \[[@R82]\]                                                                                                                                                   

  2015, Alessandro\              Cohort             Prostate cancer        97                 Ion Torrent Sequencing         AR                                     Plasma AR sequencing can identify primary resistance to abiraterone.
  Romanel \[[@R83]\]                                                                                                                                                

  2016, Samanta\                 Cohort             Prostate cancer        59                 RT-PCR, ddPCR                  AR                                     Detection of circulating AR copy number gain is a non-invasive biomarker for outcome of patients with CRPC treated with enzalutamide.
  Salvi \[[@R84]\]                                                                                                                                                  

  2017, Sumanta K.\              Prospective,\      Renal cell\            220                HiSeq 2500 Illumina            73 cancer-related genes                Higher rates of detection by ctDNA analysis after systemic therapy compared with baseline was noted for *NF1, TP53*, and *VHL*, indicating\
  Pal \[[@R87]\]                 cohort             carcinoma                                                                                                       clonal evolution of genomic alterations.

  2018, Neeraj\                  Cohort             Urothelial\            369                HiSeq 2500 Illumina            73 cancer-related genes                ctDNA NGS identified similar genomic alterations with tumor tissue. The genomic landscape was similar between lower tract and upper\
  Agarwal \[[@R89]\]                                carcinoma                                                                                                       tract urothelial carcinoma.

  2017, Emil\                    Cohort             Urothelial\            831                ddPCR                          FGFR3 and PIK3CA                       ctDNA levels in the urine and plasma were positively correlated and indicated that higher levels of *FGFR3-* and *PIK3CA*-mutated DNA\
  Christensen \[[@R91]\]                            carcinoma                                                                                                       can predict disease progression.

  **Skin cancer**                                                                                                                                                   

  2016, Gregory A.\              Cohort             Melanoma               43                 ddPCR                          *NRAS*, *BRAF*                         ctDNA had a higher sensitivity than LDH to detect disease progression.
  Chang \[[@R92]\]                                                                                                                                                  

  2016, Anne C.\                 Cohort             Melanoma               38                 RT-PCR                         *BRAF*                                 ctDNA *BRAF* mutation is a prognostic factor of OS and it is correlated with tumor burden.
  Knol \[[@R93]\]                                                                                                                                                   

  2015, Elin S.\                 Cohort             Melanoma               48                 ddPCR                          *NRAS*, *BRAF*                         ctDNA is a biomarker of response to kinase inhibitor therapy and it can be used to monitor resistance to treatment.
  Gray \[[@R94]\]                                                                                                                                                   

  2015, Maria\                   Cohort             Melanoma               22                 TaqMan assay PCR               *BRAF*                                 Detection and accurate quantification of low- *BRAF* V600E in ctDNA can predict treatment outcome.
  Gonzalez-Cao \[[@R95]\]                                                                                                                                           

  2016, Ademi\                   Cohort             Melanoma               732                PCR-based BEAMing              *BRAF*                                 *BRAF* mutation using ctDNA analysis can be detected in \>75% of patients and is a prognostic marker.
  Santiago-Walker \[[@R96]\]                                                                                                                                        

  2016, Max\                     Cohort             Melanoma               36                 qPCR                           *BRAF*                                 Quantitative analysis of *BRAF* mutation in ctDNA is a monitoring tool during treatment with BRAF/MEK inhibitors.
  Schreuer \[[@R97]\]                                                                                                                                               

  2017, Stephen Q.\              Cohort             Melanoma               52                 Amplicon sequencing, ddPCR     *NRAS*, *BRAF*                         ctDNA is a powerful complementary modality to functional imaging for real-time monitoring of tumor burden and genomic changes\
  Wong \[[@R98]\]                                                                                                                                                   throughout therapy.

  2018, R.\                      Cohort             Melanoma               161                QX200 ddPCR                    *NRAS*, *BRAF*                         ctDNA predicts relapse and survival in high-risk resected stage II/III melanoma and can help select patients for adjuvant therapy.
  Jeffrey Lee \[[@R99]\]                                                                                                                                            

  **Sarcoma**                                                                                                                                                       

  2016, Manuela\                 Cohort             Ewing                  20                 AccuPrime Taq DNA PCR          *EWSR1-FLI1* fusion                    Detection of EWSR1 fusion sequence in plasma is a promising noninvasive biomarker for improved therapeutic monitoring.
  Krumbholz \[[@R101]\]                                                                                                                                             

  2016, Masanori\                Cohort             Ewing                  3                  ddPCR                          EWS-ETS                                Tumor specific EWS-ETS translocation breakpoints in plasma DNA is a highly personalized biomarker for relapsed disease.
  Hayashi \[[@R102]\]                                                                                                                                               

  2018, David S.\                Cohort             Ewing,\                166                Illumina HiSeq 2500            EWSR1, FUS,\                           Detectable ctDNA in patients with localized disease is associated with inferior event-free survival and OS at 3 years compared to patients\
  Shulman \[[@R103]\]                               osteosarcoma                                                             CIC, CCNB3,\                           with undetectable ctDNA levels.
                                                                                                                             TP53, STAG2                            

  2013, Jacqueline\              Prospective\       Gastrointestinal\      38                 RT-PCR                         CKIT, PDGFRA                           ctDNA harboring *CKIT* or *PDGFRA* was correlated with disease course.
  Maier \[[@R104]\]              cohort             stromal tumor                                                                                                   

  2014, Changhoon\               Cohort             Gastrointestinal\      30                 PCR-based BEAMing              *CKIT, PDGFRA, BRAF*                   Genotyping of the KIT gene in exon 17 of serum ctDNA identified mutations associated with resistance to dovitinib.
  Yoo \[[@R105]\]                                   stromal tumor                                                                                                   

  2016, Noriko\                  Cohort             Gastrointestinal\      4                  Sanger sequencing,\            *C-KIT*                                Detection of secondary C-KIT mutations in ctDNA is useful to select targeted agents and to predict antitumor effects.
  Wada \[[@R106]\]                                  stromal tumor                             PCR                                                                   

  2018, Nicholas C.\             Cohort             Soft tissue\           11                 Ion AmpliSeq                   57 cancer-related genes                ctDNA analysis detected TP53/PIK3CA mutations concordant with the primary tumor in 2 of 4 cases.
  Eastley \[[@R107]\]                               sarcoma                                                                                                         

  **Brain tumors**                                                                                                                                                  

  2013, Mohamad A.\              Prospective        Glioblastoma           13                 Illumina HiSeq                 EGFR (vIII deletion)                   ctDNA analysis identified the EGFRvIII deletion in 3 of 13 patients, which was correlated with tumor tissue analysis and may help select\
  Salkeni \[[@R108]\]                                                                                                                                               patients for targeted therapy. ctDNA levels were correlated with the extent of tumor.

  2016, Shigeki\                 Retrospective      Neuroblastoma          151                Real-time quantitative PCR     MYCN                                   Serum MYCN amplification (sensitivity 86%, specificity 95% compared with tissue analysis) was associated with OS. It may help select\
  Yagyu \[[@R109]\]                                                                                                                                                 treatment prior to tumor biopsy, particularly for patients \< 18 months\
                                                                                                                                                                    (risk assessment and treatment depend on MYCN amplification status).

  2012, Blandine\                Prospective        Glioma                 80 patients,\      Digital PCR,\                  *IDH1*                                 The *IDH1* R132H mutation was identified in plasma (specificity, 100%; sensitivity related to the tumor volume and contrast enhancement).\
  Boisselier \[[@R110]\]                                                   31 controls        Agilent\                                                              It may help in the diagnosis of patients not amenable to biopsy.
                                                                                              technologies                                                          

  **Lymphoma**                                                                                                                                                      

  2016, Vincent\                 Cohort             Hodgkin                94                 TaqMan assay PCR               XPO1                                   The XPO1 E571K mutation in ctDNA can be used as a novel biomarker in diagnosis and detection of minimal residual disease.
  Camus \[[@R111]\]                                                                                                                                                 

  2016, Sarit E.\                Phase 2 trial      Diffuse large\         40                 ddPCR                          CREBBP, EP300,\                        Increase in ctDNA levels at 15 days after treatment initiation was associated with resistance to treatment.
  Assouline \[[@R112]\]                             B-cell                                                                   MLL2, FAS,\                            
                                                                                                                             STAT6, TP53                            

  2016, Florian\                 Case control       Diffuse large\         92 patients,\      CAPP-Seq                       BCL2, BCL6, MYC, IGH                   ctDNA levels at diagnosis were strongly correlated with clinical indices and were independently predictive of patient outcomes.
  Scherer \[[@R113]\]                               B-cell                 24 controls                                                                              

                                                                                                                                                                    

  2015, David M.\                Prospective\       Diffuse large\         75                 RT-PCR                         Immunoglobulin high-throughput\        ctDNA immunoglobulin high-throughput sequencing preceded radiologic evidence of recurrent disease indicating that it may be a\
  Kurtz \[[@R114]\]              cohort             B-cell                                                                   sequencing (Ig-HTS)                    surrogate marker for monitoring disease after complete remission.

  2015, Mark\                    Retrospective\     Diffuse large\         126                LymphoSIGHT™                   VDJ                                    After first-line treatment, disease progression was evident on imaging studies a median of 3.5 months after detection on ctDNA analysis\
  Roschewski \[[@R115]\]         analysis           B-cell                                                                                                          of the clonal Ig gene sequence.

  **Across Tumor Types**                                                                                                                                            

  2012, Geraldine\               Cohort from\       Colorectal,\           105                Sequenom\                      KRAS, BRAF, PIK3CA                     ctDNA analysis has potential clinical multi-purpose utility in patients with advanced cancer.
  Perkins \[[@R117]\]            multiple phase\    breast,\                                  MassArray,\                                                           
                                 1 trials           melanoma,\                                OncoCarta PCR                                                         
                                                    prostate,\                                                                                                      
                                                    ovarian,\                                                                                                       
                                                    and other                                                                                                       

  2015, Filip\                   Cohort from\       Colorectal,\           157                PCR-based\                     BRAF, EGFR, KRAS, PIK3CA               Patients with \> 1% of mutant ctDNA had shorter median OS compared to patients with ≤ 1%.
  Janku \[[@R118]\]              multiple phase\    melanoma,\                                BEAMing                                                               
                                 1 trials           non-small\                                                                                                      
                                                    cell lung,\                                                                                                     
                                                    and other                                                                                                       

  2014, Chetan\                  Cohort             Pancreatic,\           640                BEAMing,\                      187 cancer-related genes               ctDNA is a broadly applicable, sensitive, and specific biomarker that can be used for clinical and research purposes in patients with\
  Bettegowda \[[@R119]\]                            ovarian,\                                 PCR-Ligation,\                                                        various tumor types.
                                                    colorectal,\                              Safe-SeqS                                                             
                                                    bladder,\                                                                                                       
                                                    gastroesophageal,\                                                                                              
                                                    breast,\                                                                                                        
                                                    melanoma,\                                                                                                      
                                                    hepatocellular,\                                                                                                
                                                    head and neck,\                                                                                                 
                                                    and other                                                                                                       

  2013, Muhammed\                Cohort             Breast,\               6                  HiSeq 2500 Illumina            *PIK3CA, RB1, GAS6, EGFR*              ctDNA analyses can complement invasive tumor biopsies to identify mutations associated with acquired drug resistance in advanced cancer.
  Murtaza \[[@R120]\]                               ovarian and lung                                                                                                

  2015, Jean Sebastien\          Cohort             Colorectal,\           39                 Ion AmpliSeq,\                 Cancer-related genes                   Targeted sequencing of ctDNA has potential clinical utility to monitor the effect of targeted therapies.
  Frenel \[[@R121]\]                                ovarian,\                                 ddPCR                                                                 
                                                    breast,\                                                                                                        
                                                    bladder,\                                                                                                       
                                                    glioblastoma,\                                                                                                  
                                                    lung\                                                                                                           
                                                    adenocarcinoma,\                                                                                                
                                                    endometrial                                                                                                     

  2016, Maria\                   Cohort             Lung,\                 171                Illumina Hi-Seq\               54 cancer-related genes                A large proportion of patients had detectable ctDNA aberration (s), among which the majority are targetable by an approved drug.
  Schwaederle \[[@R122]\]                           breast,\                                  2500                                                                  
                                                    glioblastoma,\                                                                                                  
                                                    genitourinary,\                                                                                                 
                                                    gastrointestinal,\                                                                                              
                                                    of unknown\                                                                                                     
                                                    primary,\                                                                                                       
                                                    and other                                                                                                       

  2016, Maria\                   Cohort             Brain,\                168                Illumina Hi-Seq\               54 cancer-related genes                ctDNA tests provide information complementary to the tissue biopsies and may be useful in determining prognosis and treatment.
  Schwaederle \[[@R123]\]                           lung,\                                    2500                                                                  
                                                    breast                                                                                                          

  2017, Yulian\                  Cohort             Skin,\                 69                 Illumina Hi-Seq\               54--70 cancer-related genes            Hyper-mutated ctDNA is correlated with response to checkpoint inhibitor-based therapy and investigation of hypermutated ctDNA\
  Khagi \[[@R124]\]                                 lung,\                                    2500                                                                  as a predictive biomarker is warranted.
                                                    breast,\                                                                                                        
                                                    glioblastoma,\                                                                                                  
                                                    genitourinary,\                                                                                                 
                                                    gastrointestinal,\                                                                                              
                                                    and other                                                                                                       
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AR: Androgen Receptor; ddPCR: droplet digital PCR; FISH: fluorescence *in situ* hybridization; IHC: immunohistochemistry; mCRPC = metastatic castration-resistant prostate cancer; Met: methylation; MRD: minimal residual disease; NCT: neoadjuvant chemotherapy; NGS: next-generation sequencing; NSCLC: non-small-cell lung carcinoma; OS = overall survival; PCR: Polymerase chain reaction; PFS: Progression free survival; qPCR: quantitative polymerase chain reaction; rtPCR: real-time Polymerase chain reaction; SCC: Squamous cell carcinoma; SNVs: single nucleotide variants.

CONCLUSIONS {#s2}
===========

ctDNA analysis is a non-invasive, cost-effective test with a potentially significant role in the early detection and diagnosis of tumors. Evolving data from clinical trials indicate the association of ctDNA with tumor burden and the usefulness of ctDNA analysis in assessment of MRD, in understanding mechanisms of resistance to treatment, and in dynamically guiding therapy. The discordance between ctDNA analysis and tumor tissue genomic analysis is attributed, at least in part, to biologic and technical differences in detection of alterations between DNA shed by the tumor in the circulatory system and DNA in tumor tissue. ctDNA is thought to reflect tumor from all sites of disease and is secreted by tumor cells, phagocyte-engulfed tumor cells, and necrotic or apoptotic tumor cells. Selected prospective trials with targeted agents incorporate ctDNA analysis to select targeted therapy. Longitudinal ctDNA analysis starting at the time of diagnosis will enrich our knowledge of the evolution of patients' tumor biology, will accelerate drug development, and will contribute to the implementation of precision medicine to improve clinical outcomes.
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